Beta Bionics Files 8-K with Updates on Common Stock Purchase Agreement and IPO Details

Beta Bionics, Inc. recently disclosed details in an 8-K filing about a Common Stock Purchase Agreement and amendments related to its initial public offering (IPO). The filing, dated January 31, 2025, included significant transactions and updates on the company’s financial and corporate activities.

Regarding the Common Stock Purchase Agreement, Beta Bionics, Inc. revealed that on January 21, 2025, the company engaged in a private placement financing with Wellington Hadley Harbor Aggregator IV, L.P. The agreement involved the purchase of 1,000,000 shares of the company’s common stock at a per share price of $17.00, coinciding with the IPO closing on January 31, 2025. Notably, the company enlisted several placement agents for the Private Placement, and a placement agent fee equivalent to 7.0% of the total purchase price of the shares was paid.

In line with the IPO activities, Beta Bionics, Inc. noted the amendments made to its Certificate of Incorporation and Bylaws. The company filed an Amended and Restated Certificate of Incorporation with the Delaware Secretary of State, effective immediately prior to the IPO’s culmination. Additionally, the adoption of amended and restated bylaws was confirmed as of January 31, 2025, post the IPO closing.

Furthermore, Beta Bionics, Inc. stated in the filing that 13,800,000 shares of its common stock were issued in the IPO, inclusive of an additional 1,800,000 shares exercised by the underwriters. The company announced the closure of the IPO at $17.00 per share, with total gross proceeds amounting to $229.1 million, before deductions. The firm highlighted that no proceeds were received from the shares sold by the selling stockholders.

The filing also included a press release dated January 31, 2025, announcing the completion of the IPO and Private Placement activities. The press release disclosed the gross proceeds from the offering and the players involved in the process, including lead bookrunners and co-managers.

Overall, the disclosure provided insights into Beta Bionics, Inc.’s recent financial activities and strategic modifications following the IPO. Investors and stakeholders can refer to the full 8-K filing for comprehensive details on the Common Stock Purchase Agreement and the company’s IPO proceedings.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Beta Bionics’s 8K filing here.

Beta Bionics Company Profile

We are a commercial-stage medical device company engaged in the design, development and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease.